Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thyroid Carcinoma, Anaplastic × atezolizumab × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2 Endocrine 2 NET 1 CNS 1

Conditions

Neuroendocrine Tumors 2 Vulvar Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Sarcoma 1 Prostatic Neoplasms 1 Pheochromocytoma 1 Paraganglioma 1 Ovarian Neoplasms 1 Gallbladder Neoplasms 1 Carcinoma, Neuroendocrine 1 Breast Neoplasms 1 Bile Duct Neoplasms 1 Adenocarcinoma 1

Interventions

zimberelimab 1 tislelizumab 1 surufatinib 1 cabozantinib 1 atezolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

93 enrolled 17 charts

CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡